By Lilly Skok Bunch – Executive Director of Greater Gift in Winston-Salem Jul 7, 2022 The clinical research system’s mistakes stem from historical events that adversely impacted racial and ethnic minorities, such as the Tuskegee experiments.
Increasing the diversity of clinical trial participants is all the rage these days. The numbers tell the story: According to Food and Drug Administration data, in 2020 75% of trial participants were white, 11% were Hispanic,
Information technology, underpinned by advancements in Cloud computing, is no longer the understudy to the scientific, R&D lead. Biotech, pharma, healthcare and medtech organizations need to understand that building a fully integrated, enterprise level digital ecosystem
Click this link to go directly to our YouTube channel, Neonatology Today Media. Hit the subscribe and notification button to enjoy the direct viewing of the interview when it is available. We would love to hear
WASHINGTON, D.C. May 2, 2022 Today, U.S. Senator Tim Kaine is highlighting small business success stories from across the Commonwealth in honor of National Small Business Week (May 1-7), a week dedicated to supporting small businesses.
As new non-COVID-related clinical trials proliferate, the need for effective global decentralized CT management is becoming even more apparent. What is needed, says Dr. Harsha Rajasimha of Jeeva Informatics, is to expand the capabilities of validated
Conducting a successful clinical trial depends on well-designed patient recruitment procedures and retaining the research participants until the completion of the study. The participants must receive information regarding the study and voluntarily agree to participate. This
JoTo PR Disruptors’ signs Jeeva Informatics, a human-centric Software as a Service (SaaS) company that is working to revolutionize the clinical trials space at scale. Diversity, more enrollment, less dropouts and more global participation are some
Clinical trials are expensive, take significant time, and can run into any number of challenges and delays. The average drug study will see a 30% patient dropout rate. What is needed, according to Virginia-based Jeeva Informatics,
Over the past two years, the testing of new medical devices, drugs and vaccines has increasingly been performed outside large medical centers. Faster enrollment, fewer dropouts and global diversification of trial participants are some of the
